The 2019 EULAR updated recommendations for the treatment of RA new state that JAK inhibitors, on the same level as bDMARDs, should be one of the first treatment added to csDMARD in patients with unfavorable prognostic markers who fail initial MTX-based therapy.
In the 2019 update of the EULAR recommendations, tsDMARDs have been placed at the same level as bDMARDs because of new evidence regarding the successful long-term efficacy and safety of JAK inhibitors.
Find out more about EULAR recommendation for the management of RA with Prof. Caporali and Prof. Sewerin
